An observational study in Endometriosis, sponsored by Francisco Algaba Chueca. Recruiting at 2 sites in Spain. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-11.
Sponsored by Francisco Algaba Chueca · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Endometriosis with a site in Spain — 13 open to participants now, 15 under way, none of them phase 3. Endometriosis · Spain.
Among the 42 studies in Endometriosis with a site in Spain, this one is one of 3 that started in 2026, is one of 8 observational ones, reaches primary completion later than 12 of the 14 other live ones, and was the 42nd registered.
924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.
Browse Endometriosis studies →13 of the 42 studies in Endometriosis with a site in Spain are open now. Recruiting first, the newest first:
Arafarma Group, S.A. · Sites in Spain
Ages 18+ · Women only
University of Seville · Sites in Spain
Ages 18+ · Women only
Fundacion Dexeus · Sites in Spain
Ages 18+ · Women only
Hospital Universitari de Bellvitge · Sites in Spain
Ages 18–45 · Women only
University of Valencia · Sites in Spain
Ages 18–45 · Women only
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 132 across 351 observational studies indexed under Endometriosis.
Median enrollment 90 across the 33 interventional studies, 70 across the 8 observational. Of the 22 that completed or were terminated, 6 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 42 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Francisco Algaba Chueca as lead sponsor.
Francisco Algaba Chueca has 1 study filed under Endometriosis — fewer than ten, so there is no comparison to draw.
7 of the studies in Endometriosis with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07270393Biogipuzkoa Health Research InstituteStudy of the Influence of the Mediterranean Diet on the Quality of Life of Patients With Endometriosis. | 2026-12-01 |
| NCT06955221Hospital Universitari de BellvitgeEffect of Alcohol Sclerotherapy on Pelvic Pain and Quality of Life in Women With Ovarian Endometriosis | 2026-12-31 |
| NCT06024109Aesculap AGPerformance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy | 2027-01 |
| NCT06876376Fundacion DexeusIntraoperative Ultrasound in Bowel Deep Endometriosis | 2027-02 |
| NCT07393958Arafarma Group, S.A.Impact of Food Supplementation on Quality of Life in Patients With Endometriosis and Pelvic Pain. | 2027-08-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 42 studies in Endometriosis with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Endometriosis is a chronic inflammatory condition characterized by the presence of endometrium-like tissue outside the uterine cavity. It is estimated to affect approximately 10% of women of reproductive age and it is associated with chronic pelvic pain and infertility, among other symptoms.
Endometriosis involves complex changes in the body's cells and immune response. For this reason, the goal of this observational study is to characterize the functional, molecular, and immunological alterations in menstrual blood-derived stem cells (MenSCs) and differentiated decidual stromal cells in women with endometriosis; to validate these findings in endometrial tissue and endometriomas; and to establish their correlation with clinical parameters, with the aim of identifying key pathogenic mechanisms and potential therapeutic targets.
The main questions it aims to answer are:
Some participants will be asked to provide menstrual blood on a single day, while others will provide samples during the first five days of menstruation. Additionally, all participants will answer questionnaires about their diet, physical activity, stress, and pain levels. Therefore, the study does not involve the evaluation of a specific intervention on the participants.
The results will enable the identification of key altered mechanisms and potential therapeutic targets, thereby contributing to the development of more effective strategies for the diagnosis and treatment of the disease.
Our study population consists of 40 women aged between 18 and 45, 20 of whom have been diagnosed with endometriosis and 20 of whom are healthy volunteers. Participants will be recruited from the Department of Gynecology and Obstetrics at the Hospital Universitari Joan XXIII in Tarragona (Spain) during routine gynecological check-ups. Healthy volunteers will be selected through individual matching with participants in the study group, considering relevant demographic and clinical variables such as age and ethnic group.
In addition, a sub-cohort of 10 women (5 per study group) will be selected from the main cohort to study in greater detail the intra-menstrual variations in the immunomodulatory properties of MenSCs. This sub-cohort will include participants who agree to provide menstrual blood samples from days 1 to 5 (both inclusive) to analyze dynamic changes in the cells obtained, while maintaining the same general inclusion and exclusion criteria as in the main study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Menstrual blood-derived stem cells collection and in vitro characterization
Menstrual-blood derived stem cells will be isolated from the menstrual blood of patients with endometriosis and healthy volunteers to be characterized in vitro.
MenSCs proliferation rate
Evaluation of the expansion capacity of MenSCs from endometriosis patients vs. healthy controls using the MTT assay.
Time frame: Through study completion (average of 3 years)
Phenotypic characterization of MenSCs
Evaluation of surface marker expression using flow cytometry to determine the phenotype of MenSCs from endometriosis patients and healthy controls.
Time frame: Through study completion (average of 3 years).
MenSC chemotaxis
Assessment of the number of T-lymphocytes and monocytes capable of migrating through a transwell membrane under the stimuli of conditioned media from MenSCs obtained from endometriosis patients and healthy controls.
Time frame: Through study completion (average of 3 years)
MenSC invasion capacity
Assessment of the number of MenSCs from endometriosis patients vs. healthy controls capable of degrading a Matrigel on a transwell membrane and migrating toward a chemoattractant.
Time frame: Through study completion (average of 3 years)
Multilineage capacity of MenSCs
The differentiation potential of MenSCs from endometriosis patients vs. healthy controls towards osteocytes, chondrocytes and adipocytes will be assessed by using specific media.
Time frame: Through study completion (average of 3 years)
Decidualitzation response to progesterone of the decidual cells differentiated from MenSCs from endometriosis patients and healthy volunteers
MenSCs will be cultured in presence of 8-Br-cAMP during 14 days, and the assessment of morphology and expression of decidual markers will be performed by RT-qPCR and ELISA assay.
Time frame: Through study completion (average of 3 years).
Apoptosis resistance assessment of the decidual cells differentiated from MenSCs from endometriosis patients and healthy volunteers
Apoptosis resistance will be evaluated by Annexin V/PI flow cytometry following induction by TNFα. Additionally, the expression of key apoptotic mediators will be quantified using RT-qPCR and Western blot.
Time frame: Through study completion (average of 3 years).
Cytokine profile of the secretome of MenSCs from endometriosis patients and healthy volunteers and their differentiated decidual cells.
The conditioned media will be assessed to determine the cytokines secreted using an ELISA assay.
Time frame: Through study completion (average of 3 years).
Cytokine profile of the endometrial and endometrioma tissues
The levels of cytokines in the conditioned media from cultured explants will be assessed by ELISA assay.
Time frame: Through study completion (average of 3 years).
Cytokine profile of the secretome of immune cells populations
The levels of cytokines in the conditioned media from lymphocytes and macrophages will be assessed by ELISA assay.
Time frame: Through study completion (average of 3 years)
Cytokine profile of the peripheral blood plasma
The levels of cytokines in peripheral blood plasma from endometriosis patients and healthy volunteers will be determined by ELISA assay.
Time frame: Through study completion (average of 3 years)
Gene expression profile of MenSCs from endometriosis patients and healthy volunteers and their differentiated decidual cells
Total RNA expression of targeted genes will be analyzed by RT-qPCR.
Time frame: Through study completion (average of 3 years)
Gene expression profile of the endometrial and endometrioma tissues
Total RNA expression of targeted genes will be analyzed by RT-qPCR.
Time frame: Through study completion (average of 3 years).
Gene expression profile of the immune cells populations
Total RNA expression of targeted genes will be analyzed by RT-qPCR.
Time frame: Through study completion (average of 3 years)
Protein expression of MenSCs from endometriosis patients and healthy volunteers and their differentiated decidual cells
Analysis of the protein expression profile via Western Blot.
Time frame: Through study completion (average of 3 years)
Protein expression in endometrial and endometrioma tissues
Analysis of the protein expression profile via Western Blot.
Time frame: Through study completion (average of 3 years)
Protein expression in immune cells populations
Analysis of the protein expression profile via Western Blot.
Time frame: Through study completion (average of 3 years)
T cells activation
T cells will be exposed to conditioned media from MenSCs from healthy volunteers and endometriosis patients. Afterwards, the levels of IL-10 and IFNy will be determined by ELISA assay.
Time frame: Through study completion (average of 3 years)
T cells proliferation rate
T cells will be exposed to conditioned media from MenSCs from healthy volunteers and endometriosis patients. Afterwards, their proliferative capacity will be assessed by MTT assay.
Time frame: Through study completion (average of 3 years)
Cytokine secretion profile of macrophages
The levels of cytokines in the supernatant of polarized macrophages after incubation with MenSC-derived conditioned media from endometriosis patients and healthy volunteers will be determined by ELISA assay.
Time frame: Through study completion (average of 3 years)
Gene expression profile of macrophages
Total RNA expression of targeted genes will be analyzed by RT-qPCR.
Time frame: Through study completion (average of 3 years)
Protein expression of macrophages
Analysis of the protein expression profile via Western Blot.
Time frame: Through study completion (average of 3 years)
Phagocytic capacity of macrophages
Assessment of the macrophages' ability to engulf fluorescently labeled apoptotic bodies from MenSCs via flux cytometry and fluorescence microscopy.
Time frame: Through study completion (average of 3 years)
Angiogenic potential of macrophages conditioned media
Evaluation of the ability of macrophage-derived conditioned media to induce tube formation (Matrigel) in Human Umbilical Vein Endothelial Cells (HUVECs).
Time frame: Through study completion (average of 3 years)
Exploration of targeted interventions to reverse the pathological phenotype of MenSCs and macrophages derived from menstrual blood.
Signaling pathways and genes involved in the altered phenotype will be blocked and silenced, respectively, to evaluate if these actions reverse the cellular response to the levels of the healthy volunteers' cells.
Time frame: Through study completion (average of 3 years).
Correlation of cellular, tissue and molecular findings with patients' clinical parameters.
The associations among the functional and immunological properties of MenSCs and macrophages, clinical parameters and dietary and behavioral habits will be stablished. These clinical parameters include endometriosis stage, pain and fertility status, and the extent and localization of the endometriosis foci.
Time frame: Through study completion (average of 3 years).
Not enrolling at this site.
Start is estimated for Apr 2026; primary completion for Oct 2027, 18 months later.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.